This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10] . The study protocol was registered with the National Institute for Health Research international prospective register of systematic reviews [11] . The study eligibility criteria are available elsewhere [11] . Briefly, the study population of interest was human subjects of any age or sex who were hospitalized with SARIs with a laboratory-confirmed or suspected viral etiology. The intervention of interest was convalescent plasma, serum, or hyperimmune immunoglobulin derived from convalescent plasma. Comparator treatments included placebo, sham therapy, or no intervention; studies with no comparator group were also included. Outcome measures were derived from the protocol research questions to ascertain the clinical effectiveness of therapy [11] . 